Avisa Pharma, a local company developing breath test technology developed at the University of New Mexico, recently completed a successful field test in Africa for tuberculosis detection. The technology was developed by UNM professors Dr. Graham Timmins and Dr. Vojo Deretic and is a 10-minute breath test using a proprietary, urea-based compound that is able to detect the presence of tuberculosis bacteria within the entire lung. The field test showed that the breath test was more sensitive than sputum cultures—currently used to test for tuberculosis. The company is also developing a portable testing device that is small enough to carry in a backpack. To read more about this disruptive technology, which is also being developed for the diagnosis of other respiratory diseases and has the added ability to monitor the effectiveness of antibiotic treatment, see Kevin Robinson-Avila’s February 1, 2016 article, “Startup develops quick breath test for TB based on UNM tech,” from the Albuquerque Journal, reprinted below.
Startup develops quick breath test for TB based on UNM tech
Kevin Robinson-Avila / Tech Bytes
Published: Monday, February 1st, 2016 at 12:02am
Updated: Monday, February 1st, 2016 at 9:24am
Doctors could soon determine if patients have tuberculosis in less than 10 minutes with a simple breath test being developed by a local startup company with technology from the University of New Mexico.
Avisa Pharma Inc., which licensed the testing process from UNM in 2010, and has been working to develop and market it, conducted its first field test on patients in South Africa last fall. The trial, which included nearly three dozen people in a region where co-infection with HIV and tuberculosis is common, produced rapid results that in some cases were even more accurate than standard sputum smear tests, said Avisa President and CEO David Joseph.
“Our success rate was very high,” Joseph said. “Three of the patients had negative smear tests, but our tests confirmed that those same patients did have tuberculosis. That shows that this test can detect disease with even more sensitivity than today’s standard tests.”
A rapid breath test for tuberculosis could provide an immense boost in global efforts to combat the disease, particularly in Africa and other developing regions where tuberculosis is rampant and access to modern medical facilities is limited.
A report from the World Health Organization released last fall called tuberculosis the world’s leading infectious disease killer, alongside HIV/AIDS, with about 1.5 million deaths in 2014. The organization said a new, rapid diagnostic system is urgently needed to help stem the disease, which currently infects nearly 10 million people globally.
The problem is lack of a reliable testing method for early detection of tuberculosis and to rapidly monitor patient progress on antibiotics to determine if treatments are working, Joseph said. Today’s sputum smear tests generally take days or weeks to confirm disease. The results can be erroneous because the sputum samples don’t provide a full examination of the lungs. And children or patients sick with AIDS and other diseases often can’t produce enough sputum for an effective test.
“We can detect tuberculosis in less than 10 minutes and it doesn’t require sputum,” Joseph said. “Since the test takes just minutes, doctors can also monitor antibiotic treatments to see if they’re working or need to change.”
The breath test was originally developed by Graham Timmins, a UNM professor of medical chemistry and toxicology, and Vojo Deretic, chair of the Molecular Genetics and Microbiology Department.
They created a urea-based drug that turns to carbon dioxide when it comes in contact with bacteria. That happens because a lot of bacteria in the lungs contain an enzyme that breaks down urea to absorb the nitrogen and other elements in it, leaving carbon dioxide behind.
The drug acts as a biomarker for the enzyme. Patients breathe the compound in and, when they exhale, the carbon dioxide levels are measured.
“The breath test shows the presence of the enzyme in the lungs, which shouldn’t be there, and the system says something is wrong and you need to probe further,” Timmins said. “It’s almost like a bacterial thermometer for the lungs.”
The compound can detect the presence of bacteria anywhere in the lungs, making the breath test more accurate than culture-based sputum samples, which examine only limited regions of the respiratory tract, Joseph said.
Since 2010, Avisa has built a portable device to measure carbon dioxide levels as patients breathe in and out. The laptop-sized machine is fairly simple to use, making it ideal for remote, rural locations, said David Karshmer, vice president for technology development.
“It’s a small, lightweight, battery-powered sampling system with a simple user interface,” Karshmer said. “We went into the field to clinics and hospitals to come up with a simple, easy-to-use design that you can put in a backpack and carry anywhere.”
The company now has a prototype, which it used in the South Africa trials, and, by midyear, Joseph expects to send the design to a contract manufacturer in Texas.
Avisa is now preparing for a large, clinical trial for approval by the U.S. Food and Drug Administration and regulatory agencies in other countries. That trial, which would likely take place in summer of 2017, would include up to 1,000 people in the U.S., Europe, China and South Africa.
Once that trial concludes, it could take up to a year to receive FDA approval, potentially paving a path to market by 2018, Joseph said. At that point, Avisa would initiate more trials to apply the technology to detection of other lung diseases, such as cystic fibrosis and chronic obstructive pulmonary disease.
That diversity in potential market applications has helped attract venture investment in the company.
Avisa has raised about $8 million in private equity to date, including a $4 million round of venture investment that closed last year. It’s now raising a later-stage, $10 million round of investment to carry the company through to its clinical trials.
Santa Fe-based Sun Mountain Capital – which manages the State Investment Council’s $150 million co-investment fund for direct investments in startup companies – has contributed several million dollars to Avisa Pharma, said Sun Mountain managing partner Brian Birk.
“We originally got interested in the technology because it has a number of different applications, not just tuberculosis,” Birk said. “And the technology itself is relatively simple, giving it a shorter path to commercial development with a reasonably low amount of capital compared with other pharmaceutical startups. Avisa is one of those local companies that’s been flying under the radar, but really doing some great stuff.”
The company now employs seven people at a 2,000-square-foot office in Santa Fe. It expects to ramp up its workforce over the next year in preparation for the clinical trial.